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Neurogenic niches in the adult mammalian brain are composed of heterogeneous populations of neural
stem cells. In this issue of Neuron, Codega et al. (2014) isolate quiescent neural stem cells from the adult
subventricular zone and demonstrate their stem cell characteristics.Adult neurogenesis is responsible for the
continuous generation and integration of
new neurons in existing neural networks.
These neurons are derived from multipo-
tent neural stem cells (NSCs) residing in
specialized neurogenic niches. The sub-
ventricular zone (SVZ) is the largest of
these niches in the adult brain and is
capable of generating at least 30,000
new neurons in rodents that then migrate
through the rostral migratory stream
(RMS) to integrate into networks in the
olfactory bulb (OB) (Lois and Alvarez-
Buylla, 1994). One of the characteristics
of tissue stem cell niches is the presence
of quiescent stem cells, but unfortunately
these quiescent cells are usually difficult
to study since attempts to culture them
or isolate them usually lead to activation.
The study by Codega et al. (2014) in this
issue of Neuron provides new insights
into the nature of quiescent NSCs in the
SVZ and also important tools that will
facilitate future studies of these cells.
In the SVZ, type B1 cells make up the
primary NSC population; they divide to
either self-renew or produce a secondary
progenitor population, the intermediate
progenitors (transit-amplifying or type C
cells) that generate various neuronal
subtypes destined for the OB, as well as
progenitors that generate glial cell types
(see Figure 1). Type B1 cells express glial
fibrillary acidic protein (GFAP+) and main-
tain a bipolar morphology, with special-
ized apical processes that extend to
receive signals from the CSF in the lateral
ventricles and basal processes that main-
tain contact with blood vessels (Merkle
et al., 2004; Mirzadeh et al., 2008; Shen
et al., 2008; Tavazoie et al., 2008). Addi-tionally, GFAP+ type B1 cells exist in
both activated (as determined by the
expression of epidermal growth factor
receptor [EGFR+]) and quiescent states
(Doetsch et al., 1999; Morshead et al.,
1994; Pastrana et al., 2009). The charac-
terization of the structure of GFAP+ type
B1 cells, along with lineage-tracing
studies, established that type B1 NSCs
in the SVZ are the source of postnatally
generated glial and neuronal cell sub-
types. However, the relative contributions
of active NSCs (aNSCs) versus quiescent
NSCs (qNSCs) in the replenishment of
type B1 cells and the production of spe-
cific neuronal and glial cell subtypes un-
der normal and pathological states have
not been elucidated. In addition, direct
observations examining the potential
precursor-product transitions between
qNSCs and aNSCs have been lacking,
with most understanding of their relation-
ship being inferred. This is largely due to
the lack of markers distinguishing qNSCs
from aNSCs hampering examination of
the lineage potentials and regenerative
capacities of the heterogeneous popula-
tion of type B1 cells in the SVZ.
In this issue of Neuron, Codega et al.
(2014) utilize a unique combination of
markers to isolate and purify qNSCs and
aNSCs from the mouse SVZ. Building
on previous findings that a subset of
purified CD133-positive (CD133+) cells
from the SVZ is capable of generating
neurons in vivo and neurospheres in vitro
(Coskun et al., 2008), as well as coex-
pressing GFAP (Beckervordersandforth
et al., 2010;Mirzadeh et al., 2008), Codega
et al. (2014) postulated and found that
cells expressing GFAP (labeled using theNeurotransgenic mouse line GFAP::GFP in
which GFP is under the control of the
GFAP promoter) and CD133 identify both
qNSCs and aNSCs among SVZ cells. A
key finding is the observation that EGFR,
a protein expressed in aNSCs (Pastrana
et al., 2009), is expressed in a much
lower percentage of GFAP+CD133+ cells
(GFAP+CD133+EGFR+). This indicates
that GFAP+ and CD133+ cells that do not
express EGFR (GFAP+CD133+EGFR+)
may belong to a distinct population of
type B1 SVZ cells, the qNSC fraction.
Indeed, unlikeGFAP+CD133+EGFR+cells,
GFAP+CD133+EGFR cells do not ex-
press proliferationmarkers, fail to incorpo-
rate bromodeoxyuridine (BrdU) after a
pulse, and survive infusion of cytosine-b-
D-arabinofuranoside (Ara-C), which effi-
ciently eliminates dividing B1 cells.
Moreover, BrdU incorporation is only
observed in GFAP+CD133+EGFR cells
after prolonged administration, indicating
thatGFAP+CD133+EGFR cells are slowly
dividing. These findings cumulatively indi-
cate that the cell cycle kinetics of GFAP+
CD133+EGFR cells differ significantly
from GFAP+CD133+EGFR+ cells, con-
sistent with quiescent stem cells found in
other tissues. Therefore, the differential
expression of GFAP, CD133, and EGFR
enabled Codega et al. (2014) to reliably
distinguish and isolate qNSCs (GFAP+
CD133+EGFR cells) and aNSCs (GFAP+
CD133+EGFR+ cells). The ability to isolate
and purify these two populations is a
gateway to understanding the molecular
and cellular characteristics of qNSCs for
the first time.
Stem cells are defined by their capacity
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Figure 1. Quiescent NSCs and Activated NSCs in Their SVZ Niche
The subventricular zone (SVZ) of the adult brain is populated by postmitotic ependymal cells and type B1
neural stem cells (NSCs), which generate transit-amplifying progenitors that will produce neuronal or as-
trocytic cells. Type B1 NSCs may be quiescent (qNSCs) or activated (aNSCs). Codega et al. (2014) distin-
guished and isolated GFAP-positive qNSCs from aNSCs based on the differential expression of molecular
factors expressed by SVZ cells. qNSCs are ciliated radial glia-like cells that express GFAP and CD133 but
not EGFR or Nestin. On the other hand, aNSCs that express GFAP, CD133, EGFR, and Nestin do not have
primary cilia. Both qNSC and aNSC can divide to either self-renew or generate aNSCs, which will in turn
divide to generate transit-amplifying progenitors that will produce either neuroblasts destined for the olfac-
tory bulb or astrocytic cell lineages. Both qNSCs and aNSCs respond to signals within the CSF. Codega
et al. (2014) identified twoCSFmolecules that regulate thequiescent state: ProstaglandinD2 (PGD2), which
acts on both qNSCs and aNSCs, and Sphingosine-1-Phosphate (S1P), which acts on qNSCs.
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in vivo transplantation studies, Codega
et al. (2014) show that GFAP+CD133+
EGFR qNSCs possess these defining
characteristics of stem cells. One month
after transplantation, progeny of trans-
planted qNSCs were found in the SVZ
and within the OB neural circuitry, indi-
cating that transplanted qNSCs are
able to self-renew and differentiate into
mature interneurons. Additionally, qNSCs
are multipotent as they are capable of
generating oligodendrocytes and mature
astrocytes in addition to neuronal
lineages.
One surprising observation is the
absence of Nestin expression in qNSCs.
The expression of Nestin, an intermediate
filament protein, has been a widely used
marker of embryonic and adult neural
stem cells. Codega and colleagues took
advantage of this additional difference
between qNSCs, aNSCs, and Nestin-
expressing ependymal cells (which have
been claimed to be able to differentiate
into neuronal or glial cells [Carle´n et al.,
2009; Coskun et al., 2008]) to examine
the regenerative properties of qNSCs
in vivo. This was accomplished by utilizing
an inducible Cre transgenic mouse line
carrying a reporter transgene, tdTomato
(GFAP::CreERT2;CAG::tdTomato). In this502 Neuron 82, May 7, 2014 ª2014 Elsevier Iexperiment, GFAP-derived SVZ cells
were labeled by administration of tamox-
ifen for 10 days, followed by a 10-day
infusion of Ara-C to eliminate all dividing
cells. Codega et al. (2014) find that many
of the tdTomato+ cells in the SVZ are
eliminated after Ara-C infusion and that
the remaining tdTomato+ cells do not
express Nestin. However, 6 days after
Ara-C removal, fractions of tdTomato+
cells began to express Nestin, and/or
doublecortin, a marker for neuroblasts,
implying that the remaining tdTomato+
cells are regenerative, as they are able
to replenish the depleted aNSC popula-
tion and contribute to the production of
neuronal lineages. Thus, qNSCs retain
long-term neurogenic potential and begs
for further investigation of the intrinsic
and extrinsic events that trigger qNSCs
to enter the activated state and differen-
tiate into neuronal or glial cell lineages.
To start to address these questions,
Codega et al. (2014) performed microar-
ray analyses that will help characterize
the molecular signature of qNSCs. These
experiments show that factors commonly
expressed by quiescent stem cell popu-
lations in tissues outside of the nervous
system are also upregulated in qNSCs,
including genes encoding cell surface
proteins/receptors and extracellular ma-nc.trix proteins. Codega et al. (2014) then
went on to show that ligands for two of
these differentially expressed receptors,
the G protein-coupled receptors for
Sphingosine-1-Phosphate (S1P) and
Prostaglandin D2, effectively inhibit the
activation of qNSCs. Notably, S1P selec-
tively acts on qNSCs but not aNSCs, indi-
cating that qNSCs can be specifically
targeted by extrinsic factors. Since the
ligands for these receptors are found in
the CSF, they may be physiologic regula-
tors of NSC quiescence. These findings,
along with the observations that qNSCs
are unable to form neurospheres in vitro
using currently established protocols, un-
derscore the need to further identify and
characterize factors that regulate qNSCs,
as well as other NSC populations, within
the SVZ neurogenic niche at different
phases of adult neurogenesis. It is also
worth noting that an S1P agonist was
recently approved as an oral treatment
for multiple sclerosis (Bolli et al., 2011).
The main mechanism of action for this
agent (fingolimod—trade name Gilenya)
is believed to be a modulation of lympho-
cyte trafficking; however, it is quite
possible that this agent might affect
qNSC dynamics. Since fingolimod is
thought of as a first in family compound
with other agents in various pipelines,
it is quite possible that S1P agonists and
antagonists could be studied for their
effects on SVZ NSCs in future studies
and in disease models.
Codega et al. (2014) provide a powerful
method that separates two major popu-
lations of type B1 NSCs in the SVZ.
Given that the SVZ is composed ofmolec-
ularly heterogeneous NSCs (Giachino
et al., 2014), future experiments must
determine and characterize the existence
of lineage-restricted qNSCs, and how
their fate potential is affected over time
under homeostatic and pathological
conditions. In addition to intracellular
and extracellular molecular factors, it
would also be interesting to examine
how other cell populations within the
SVZ affect the behavior and maintenance
of qNSCs. Advancing our knowledge on
the biology and plasticity of qNSCs is
especially valuable since the adult human
brain harbors largely quiescent NSC pop-
ulations (van denBerge et al., 2010). Thus,
by harnessing the regenerative potential
of quiescent NSCs, new approaches
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Previewsmay be developed to effectively treat
neurological diseases, particularly those
caused by cellular dysfunction or tissue
injury.
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Itch is immensely frustrating. Most studies focus on the cause of itch. In this issue of Neuron, Kardon et al.
(2014) find that itch can be modulated by inhibitory neurons that produce dynorphin, an endogenous agonist
of k-opioid receptors.Scientific investigations can be likened to
scratch tickets. While individual experi-
ments that we perform may not pan out,
the study by Kardon et al. (2014) in this
issue of Neuron is a winner. These inves-
tigators characterize a population of
spinal inhibitory neurons and demon-
strate that dynorphin, released from these
neurons, is a backscratcher responsible
for modulating itch (Figure 1).
Itch, also referred to as pruritus, may
have evolved as a protective mechanism
against threats from arthropods, but it is
a prominent feature of inflammatory skin
disease and ruins the lives of patients
with chronic renal failure, liver disease,
and certain malignancies. Its impact on
quality of life is comparable to that ofpain (Kini et al., 2011). It has been sug-
gested that itch be considered a disease
(Yosipovitch, 2011). Drugs with itch as
an approved indication are limited to
antihistamines and topical steroids and
have limited effectiveness. It is recog-
nized that neuromodulators can be re-
markably effective in treating some itches
and that scratching may provide tem-
porary relief and feel pleasurable, sug-
gesting that complex neurocircuitry
and neuromodulatory mechanisms are
involved. Accordingly, endogenous mole-
culesmay have the potential to reduce the
sensation of itch.
Understanding the underlying mecha-
nisms of itch is an intense focus of inves-
tigation. Recent advances include theidentification of a series of itch-related
ligands and receptors as well as peri-
pheral neurons and spinal afferents
specialized in transmitting this sensation
and distinguishing it from pain (Han
et al., 2013; Mishra and Hoon, 2013). It
is recognized that itch and pain are part
of a complex family dynamic. A few exam-
ples are scratching, which alleviates itch
but is a noxious stimulus, m-opioids,
which relieve pain but induce itch, and
the inhibition of glutaminergic transmis-
sion from nociceptors, which reduces
pain but increases scratching (Lager-
stro¨m et al., 2010; Liu et al., 2010).
A key role in sensory processes has
been suggested for inhibitory circuits in
the spinal cord, consistent with then 82, May 7, 2014 ª2014 Elsevier Inc. 503
